Slowing revenue growth hurts online drug platform YSB
The B2B drug distributor posted higher annual revenues and swung to an adjusted profit, but disappointed investors still sent the firm’s stock down 9% on the day after the earnings…
Recent Articles
RELATED ARTICLES
-
Its growth cooling, can Kanzhun stay employed in a slowing economy?
2076.HK BZ.US -
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Gig-work platform EPWK tests investors with upsized IPO plan
-
Blue Moon shadowed by aggressive promotional spending in slowing economy
6993.HK
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
